Al-Saleh Jamal, el-Eissawy Sabrine
Department of Internal Medicine (Rheumatology), Faculty of Medicine For Girls, Al Azhar University, Cairo, Egypt.
Egypt J Immunol. 2006;13(2):41-8.
The chemokine receptors expression dictates the spectrum of action of chemokines. One possible role of chemokines in autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), is to facilitate the migration of lymphocytes to specific target organs thus accounting for the accumulation of T-cells in different organs, and subsequent disease manifestations. In the present study we investigated the surface expression of the chemokine receptors CXCR3 and CCR5 on CD4-positive T-helper lymphocytes in patients with active SLE, patients in remission, and in healthy subjects. Furthermore, a possible correlation between these cytokine receptors and SLE disease activity index (SLEDAI) was investigated. The study included 48 patients; all met at least four of the 11 American College of Rheumatology (ACR) diagnostic criteria for SLE. They were subdivided according to their SLEDAI into 2 groups: active SLE group of 28 patients with SLEDAI (> or = 6), and 20 SLE patients in remission with SLEDAI (< 6). Twenty age and sex matching healthy subjects were included as controls. We found that patients in the active SLE group had significantly elevated the mean expressions of CXCR3 and CCR5 on the surface of CD4+ T-lymphocytes than in the SLE patients in remission and healthy controls. The SLE patients in remission were found to have substantial reduced CD4+ CXCR3+ expression in comparison to healthy controls. Interestingly, a significant positive correlation was found between SLEDAI and each mean level of CD4+ CXCR3 and CD4+ CCR5+ in all SLE patients. In conclusion, this study revealed that the surface expression of the chemokine receptors CXCR3 and CCR5 on CD4+ T cells were increased markedly in patients with active SLE more than SLE patients in remission and the healthy subjects, this increase correlated positively with the SLEDAI. A larger study should be conducted to examine the role of CXCR3 and CCR5 expression in predicting disease activity in SLE patients.
趋化因子受体的表达决定了趋化因子的作用谱。趋化因子在自身免疫性疾病(如系统性红斑狼疮,SLE)中的一个可能作用是促进淋巴细胞向特定靶器官迁移,从而解释T细胞在不同器官中的积聚以及随后的疾病表现。在本研究中,我们调查了活动期SLE患者、缓解期患者以及健康受试者中趋化因子受体CXCR3和CCR5在CD4阳性辅助性T淋巴细胞表面的表达情况。此外,还研究了这些细胞因子受体与SLE疾病活动指数(SLEDAI)之间的可能相关性。该研究纳入了48例患者;所有患者均至少符合美国风湿病学会(ACR)11项SLE诊断标准中的4项。根据SLEDAI将他们分为2组:28例SLEDAI(≥6)的活动期SLE组和20例SLEDAI(<6)的缓解期SLE患者。纳入20名年龄和性别匹配的健康受试者作为对照。我们发现,活动期SLE组患者CD4 + T淋巴细胞表面CXCR3和CCR5的平均表达明显高于缓解期SLE患者和健康对照。与健康对照相比,缓解期SLE患者的CD4 + CXCR3 +表达大幅降低。有趣的是,在所有SLE患者中,SLEDAI与CD4 + CXCR3和CD4 + CCR5 +的各平均水平之间均存在显著正相关。总之,本研究表明,活动期SLE患者CD4 + T细胞上趋化因子受体CXCR3和CCR5的表面表达明显高于缓解期SLE患者和健康受试者,这种增加与SLEDAI呈正相关。应开展更大规模的研究来探讨CXCR3和CCR5表达在预测SLE患者疾病活动中的作用。